Cited by 18Inflammatory Bowel DiseaseLiver Diseases and ImmunityOcular Diseases and Behçet’s Syndrome

The natural history of newly diagnosed ulcerative colitis in patients with concomitant primary sclerosing cholangitis

Open access
Khan, Nabeel, Trivedi, Chinmay, Shah, Yash, Cole, Elisabeth, Lewis, James, Yang, Yu-Xiao·2018·Inflammatory Bowel Diseases

Abstract

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is commonly associated with ulcerative colitis (UC). Our aim was to compare the course of disease in patients with UC-PSC and UC alone in a nationwide cohort. METHODS: We conducted a retrospective cohort study among nation-wide Veterans Affairs (VA) patients newly diagnosed with UC to determine the association between PSC status and clinical outcomes related to UC disease course. This study was divided into 2 groups of patients: (1) The incident UC-PSC group and (2) the incident UC-alone group. Follow-up began at the time of index colonoscopy that diagnosed UC and ended at the first occurrence of the respective outcome for the regression analysis of the following censoring events: (1) colectomy, (2) death, (3) end of follow-up, and (4 lost to follow-up. RESULTS: The analysis included 836 UC patients without PSC and 74 UC-PSC patients. In univariate comparisons, PSC patients were more likely to have more extensive UC than those without PSC. In a multivariable Cox regression analysis adjusting for sex, age at UC diagnosis, race, severity of UC, and extent of UC, PSC status was not associated with the risk of colectomy for UC, increased risk of receiving ≥ 2 courses of steroids for UC, or with the risk of receiving immunomodulators for UC. CONCLUSION: UC-PSC patients do not have a more benign disease course than UC patients without PSC. UC-PSC patients may have a modestly increased risk for multiple courses of steroids, which may be mediated by more extensive colonic involvement.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ibd/izy106

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • More recent comparisons show similar needs for courses of steroids and treatment with immunomodulators in UC patients with and without PSC.

    “More recently the natural history from onset of UC in patients with and without PSC have been compared and similar needs regarding courses of steroids and treatment with immunomodulators were shown.365”

    From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [365]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. LaRusso NF, Wiesner RH, Ludwig J, et al. Current concepts. Primary sclerosing cholangitis. N Engl J Med. 1984;310:899-903.

Cited by

Sorted by citations

Authors
Khan, N., Trivedi, C., Shah, Y., Cole, E., Lewis, J., & Yang, Y.-X.
Affiliations
  • University of Pennsylvania (US)
  • Section of Gastroenterology, Corporal Michael J. Crescenz Medical Center, Pennsylvania, USA
  • James J. Peters VA Medical Center (US)
  • Children's Hospital of Pittsburgh (US)
Corresponding author
Khan, Nabeel
Venue
Inflammatory Bowel Diseases
Published
2018-04-25
Volume
24
Issue
9
Pages
2062-2067
ISSN
  • 1078-0998 (ISSN-L)
  • 1536-4844
OpenAlex
W2801709134
Cited by
18
References
26
Citations by year
2026: 4 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 3
FWCI
1.53
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Inflammatory Bowel Diseases (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • Gilead Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
ulcerative colitis, primary sclerosing cholangitis
MeSH terms
Adult, Colitis, Ulcerative, Female, Humans, Male, Middle Aged, Regression Analysis, Retrospective Studies, Risk Factors, Severity of Illness Index, Cholangitis, Sclerosing, Proportional Hazards Models, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review